Non-Sterile Liquids and Suspensions Market Size to Hit USD 95.25 Million by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-sterile Liquids and Suspensions Market

5.1. COVID-19 Landscape: Non-sterile Liquids and Suspensions Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-sterile Liquids and Suspensions Market, By Dosage Form / Product Type

8.1. Non-sterile Liquids and Suspensions Market Revenue and Volume Forecast, by Dosage Form / Product Type

8.1.1. Oral solutions (clear solutions, syrups, elixirs)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Oral suspensions (reconstitutable powders / ready-to-use suspensions)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Topical non-sterile liquids (lotions, liniments)

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Emulsions (oil-in-water, water-in-oil)

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Ophthalmic/otic non-sterile rinses (OTC ear/nasal washes — non-sterile where applicable)

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Mouthwashes / oral rinses (therapeutic and OTC)

8.1.6.1. Market Revenue and Volume Forecast

Chapter 9. Global Non-sterile Liquids and Suspensions Market, By Therapeutic Area / Indication

9.1. Non-sterile Liquids and Suspensions Market Revenue and Volume Forecast, by Therapeutic Area / Indication

9.1.1. Respiratory (cough syrups, pediatric antibiotics)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. CNS & pain (liquid analgesics, antiepileptics)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Anti-infectives (oral antibiotic suspensions)

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Gastrointestinal (antacids, oral rehydration solutions)

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Dermatological (topical lotions/liniments)

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Nutraceuticals & pediatric nutritional liquids

9.1.6.1. Market Revenue and Volume Forecast

Chapter 10. Global Non-sterile Liquids and Suspensions Market, By User / End Market

10.1. Non-sterile Liquids and Suspensions Market Revenue and Volume Forecast, by User / End Market

10.1.1. Prescription pharmaceuticals (Rx oral suspensions & solutions)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. OTC/consumer health liquids (cough syrups, OTC analgesic liquids)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Hospital formularies (bulk/ward-use non-sterile liquids)

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Compounding pharmacies (custom non-sterile preparations)

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Non-sterile Liquids and Suspensions Market, By Sales / Distribution Channel

11.1. Non-sterile Liquids and Suspensions Market Revenue and Volume Forecast, by Sales / Distribution Channel

11.1.1. Retail pharmacies & drugstores

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Hospital / institutional procurement

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. e-commerce & direct-to-consumer (OTC liquids)

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Wholesalers/specialty distributors

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Non-sterile Liquids and Suspensions Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.1.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.1.3. Market Revenue and Volume Forecast, by User / End Market

12.1.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.1.5.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.1.5.3. Market Revenue and Volume Forecast, by User / End Market

12.1.5.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.1.6.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.1.6.3. Market Revenue and Volume Forecast, by User / End Market

12.1.6.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.2.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.2.3. Market Revenue and Volume Forecast, by User / End Market

12.2.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.2.5.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.2.5.3. Market Revenue and Volume Forecast, by User / End Market

12.2.5.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.2.6.3. Market Revenue and Volume Forecast, by User / End Market

12.2.6.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.2.7.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.2.7.3. Market Revenue and Volume Forecast, by User / End Market

12.2.7.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.2.8.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.2.8.3. Market Revenue and Volume Forecast, by User / End Market

12.2.8.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.3.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.3.3. Market Revenue and Volume Forecast, by User / End Market

12.3.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.3.5.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.3.5.3. Market Revenue and Volume Forecast, by User / End Market

12.3.5.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.3.6.3. Market Revenue and Volume Forecast, by User / End Market

12.3.6.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.3.7.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.3.7.3. Market Revenue and Volume Forecast, by User / End Market

12.3.7.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.3.8.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.3.8.3. Market Revenue and Volume Forecast, by User / End Market

12.3.8.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.4.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.4.3. Market Revenue and Volume Forecast, by User / End Market

12.4.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.4.5.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.4.5.3. Market Revenue and Volume Forecast, by User / End Market

12.4.5.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.4.6.3. Market Revenue and Volume Forecast, by User / End Market

12.4.6.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.4.7.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.4.7.3. Market Revenue and Volume Forecast, by User / End Market

12.4.7.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.4.8.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.4.8.3. Market Revenue and Volume Forecast, by User / End Market

12.4.8.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.5.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.5.3. Market Revenue and Volume Forecast, by User / End Market

12.5.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.5.5.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.5.5.3. Market Revenue and Volume Forecast, by User / End Market

12.5.5.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Dosage Form / Product Type

12.5.6.2. Market Revenue and Volume Forecast, by Therapeutic Area / Indication

12.5.6.3. Market Revenue and Volume Forecast, by User / End Market

12.5.6.4. Market Revenue and Volume Forecast, by Sales / Distribution Channel

Chapter 13. Company Profiles

13.1. Catalent Pharma Solutions

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerDosage Form / Product Typeance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific (Patheon)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerDosage Form / Product Typeance

13.2.4. Recent Initiatives

13.3. Recipharm

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerDosage Form / Product Typeance

13.3.4. Recent Initiatives

13.4. PCI Pharma Services

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerDosage Form / Product Typeance

13.4.4. Recent Initiatives

13.5. Fareva

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerDosage Form / Product Typeance

13.5.4. Recent Initiatives

13.6. Piramal Pharma Solutions

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerDosage Form / Product Typeance

13.6.4. Recent Initiatives

13.7. Abbott

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerDosage Form / Product Typeance

13.7.4. Recent Initiatives

13.8. Aenova Group

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerDosage Form / Product Typeance

13.8.4. Recent Initiatives

13.9. Almac Group

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerDosage Form / Product Typeance

13.9.4. Recent Initiatives

13.10. Jubilant Pharmova (Jubilant Life Sciences)

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerDosage Form / Product Typeance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The non-sterile liquids and suspensions market size is expected to increase from USD 48.06 million in 2024 to USD 95.25 million by 2034.

The non-sterile liquids and suspensions market is expected to grow at a compound annual growth rate (CAGR) of around 7.08% from 2025 to 2034.

The major players in the non-sterile liquids and suspensions market include Catalent Pharma Solutions, Thermo Fisher Scientific (Patheon), Recipharm, PCI Pharma Services, Fareva, Piramal Pharma Solutions, Aenova Group, Almac Group, Jubilant Pharmova (Jubilant Life Sciences), SB Pharmco (SB Pharmco Puerto Rico / S. B. Pharma), Kindeva Drug Delivery, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Cipla Ltd., Aurobindo Pharma, Teva Pharmaceutical Industries, Viatris (Mylan legacy), Novartis (Sandoz division), and Pfizer Inc.

The driving factors of the non-sterile liquids and suspensions market are the rising demand for oral medications, ease of administration, pediatric and geriatric preference, cost-effectiveness, expanding pharmaceutical production, and increasing prevalence of chronic diseases.

North America region will lead the global non-sterile liquids and suspensions market during the forecast period 2025 to 2034.